Discover
CLDX
Celldex Therapeutics, Inc.
38.24
1 x 32.58
1 x 43.72
bid
ask
-
0.74
1.90%
1 @ 05:08 AM
39.02 +0.78 (2.04%)
| Ytd | 40.80% | |
| 1y | 47.53% |
37.53
day range
38.87
22.10
52 week range
45.14
| Open | 38.87 | Prev Close | 38.98 | Low | 37.53 | High | 38.87 | Mkt Cap | 3.00B |
| Vol | 2.08M | Avg Vol | 1.01M | EPS | -4.35 | P/E | N/A | Forward P/E | -9.05 |
| Beta | 0.84 | Short Ratio | 10.28 | Inst. Own | 110.27% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 39.12 | 200-d Avg | 32.12 | 1yr Est | 59.07 |
CLDX News
defenseworld.net
Head-To-Head Survey: Celldex Therapeutics (NASDAQ:CLDX) & Bicycle Therapeutics (NASDAQ:BCYC)
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Bicycle Therapeutics (NASDAQ: BCYC - Get F
defenseworld.net
Engineers Gate Manager LP Takes $1.26 Million Position in Celldex Therapeutics, Inc. $CLDX
Engineers Gate Manager LP acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ: CLDX) in the u
defenseworld.net
Head-To-Head Comparison: Precigen (NASDAQ:PGEN) and Celldex Therapeutics (NASDAQ:CLDX)
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Precigen (NASDAQ: PGEN - Get Free Report)
defenseworld.net
Seres Therapeutics (NASDAQ:MCRB) and Celldex Therapeutics (NASDAQ:CLDX) Head to Head Review
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Seres Therapeutics (NASDAQ: MCRB - Get Fre
benzinga.com
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweig